Biosimilars are a prescription for better health.
Biosimilars could lead to over $54 billion in savings over the next ten years, giving 1.2 million patients access to needed medicines.
The Biosimilars Council is a division of the Association for Accessible Medicines.
We work to ensure a positive regulatory and policy environment for biosimilar medicines through educating the public and patients about the potential of biosimilar medicines.
Utilization of innovative and very costly medicines is expected to grow exponentially in the coming years. With biosimilars, these advanced treatments are poised to become available at a lower cost to millions of patients in the United States. A positive regulatory environment can increase biosimilar adoption.
Read coverage of biosimilars in the news, hear more from experts on the potential of biosimilars, and learn about Biosimilars Council efforts to increase biosimilar access for patients.
Enter your email address below and receive the Biosimilars Bulletin – our monthly newsletter with the most recent information on biosimilars in the United States.
Register for GRx+Biosims 2019 on November 4-6, 2019 in Bethesda, Maryland to hear top officials and subject matter experts from the U.S. Food and Drug Administration (FDA), industry and academia, all designed to enhance understanding and knowledge sharing of the latest technical, policy, and regulatory information and expectations of the industry.
These resources provide answers around what biosimilars are, why they are important, how they can improve patient access, and how they can save the United States billions of dollars.
Sign up for Biosimilars Council Newsletter to hear about the field, learn about events, and find out how you can make an impact.